Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $136M | $116M | $64.0M | $54.6M | $69.8M | $93.6M | $50.9M | — |
| Revenue growth | — | -14.3% | -45.0% | -14.7% | 28.0% | 34.1% | -45.6% | — |
| Gross profit | $48.1M | $34.5M | $15.2M | $6.41M | $11.6M | $19.3M | $9.92M | — |
| Gross margin | 35.4% | 29.7% | 23.8% | 11.8% | 16.6% | 20.6% | 19.5% | — |
| Operating income | $5.39M | -$22.4M | -$29.3M | -$38.0M | -$14.3M | $513K | -$3.10M | -$5.41M |
| Operating margin | 4.0% | -19.3% | -45.7% | -69.6% | -20.5% | 0.5% | -6.1% | — |
| Net income | $1.28M | -$25.8M | -$29.9M | -$38.6M | -$14.1M | -$90.0K | -$33.6M | -$20.7M |
| Net margin | 0.9% | -22.2% | -46.8% | -70.8% | -20.2% | -0.1% | -66.1% | — |
| EPS (diluted) | -$2.57 | -$1.39 | -$6.48 | -$4.08 | -$0.49 | -$0.02 | -$128.37 | -$28.58 |
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $3.86M | -$33.5M | -$10.6M | -$38.5M | -$12.4M | -$4.05M | -$8.49M | -$23.5M |
| Capital expenditures | $787K | $992K | $11.0K | $46.0K | $8.00K | $36.0K | $214K | — |
| Free cash flow | $3.07M | -$34.5M | -$10.6M | -$38.5M | -$12.4M | -$4.09M | -$8.70M | — |
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $13.0M | $11.3M | $22.1M | $11.2M | $13.2M | $9.40M | $5.34M | $1.30M |
| Total assets | $67.3M | $55.5M | $50.3M | $41.1M | $53.7M | $56.0M | $39.7M | $43.9M |
| Total liabilities | $62.2M | $29.9M | $21.9M | $22.5M | $33.6M | $33.7M | $45.4M | $50.6M |
| Long-term debt | $13.5M | $10.2M | $362K | $66.0K | — | — | — | $5.07M |
| Shareholders' equity | $5.13M | $25.5M | $28.4M | $18.6M | $20.0M | $22.4M | -$5.70M | -$7.96M |
| Retained earnings | -$144M | -$166M | -$196M | -$235M | -$250M | -$250M | -$284M | -$304M |
| Shares (wtd avg diluted) | 15.6M | 20.4M | 6.63M | 9.46M | 28.9M | 4.29M | 262K | 723K |
Every figure is extracted from DNA X, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.